Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;64 Suppl 1(Suppl 1):13-28.
doi: 10.1111/ijd.17793. Epub 2025 Apr 23.

Basic Emollients for Xerosis Cutis in Atopic Dermatitis: A Review of Clinical Studies

Affiliations
Review

Basic Emollients for Xerosis Cutis in Atopic Dermatitis: A Review of Clinical Studies

Andreas Wollenberg et al. Int J Dermatol. 2025 Jun.

Abstract

Xerosis cutis (dry skin) is a common and burdensome symptom of atopic dermatitis (AD). Topical emollients restore skin hydration and barrier function through the physicochemical properties of their nonactive constituents (e.g., glycerol, urea, lactic acid, liquid paraffin, petrolatum) and represent the mainstay of basic therapy for xerosis cutis associated with AD. Newer "emollients plus" containing active ingredients may expand the treatment options available to patients with AD; however, we believe that basic emollients remain an important strategy for the long-term management of xerosis cutis. To that end, this article aims to review the clinical value of basic emollients for treating xerosis cutis in AD. We performed a series of literature searches to identify clinical studies of basic emollients containing one or more of the following ingredients: almond and coconut oils, amino acids, chondroitin, dexpanthenol, glucose, glycerol, glycosaminoglycans, hyaluronic acid, lactic acid, lanolin, olive oil, paraffin, petrolatum, phospholipids, polyunsaturated fatty acids, pyroglutamic acid, squalene, triglycerides, urea, vegetable oils, and vitamin E. From these searches, the authors identified articles of interest that described the efficacy of basic emollients for the treatment of xerosis cutis associated with AD. Studies included in our review varied widely in terms of sample size, study design, interventions, and endpoints but collectively showed that most basic emollient formulations are safe and effective at improving objective and subjective measures of xerosis cutis. These studies also demonstrated the importance of ongoing emollient therapy to avoid xerosis relapse and the additive benefits of emollients that combine ingredients with complementary biophysical properties (e.g., glycerol with its humectant effect plus petrolatum with its occludent effect). Overall, the current body of literature reinforces the role of basic emollients as effective and accessible treatment options for the long-term management of xerosis cutis in patients with AD.

Keywords: atopic dermatitis; dry skin; eczema; emollient; moisturizer; xerosis cutis.

PubMed Disclaimer

Conflict of interest statement

A.W. has served as an advisor, speaker or investigator for AbbVie, Aileens Pharma, Almirall, Amgen, Beiersdorf, Bioderma, Bristol Myers Squibb, Eli Lilly, Galapagos, Galderma, Glenmark, GSK, Hans Karrer, Janssen, LEO Pharma, L'Oreal, Maruho, Merck (MSD), Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi‐Aventis, Sandoz, and UCB. S.B. reports support for the present manuscript from Pierre Fabre; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AbbVie, Alexion, Almirall, AstraZeneca, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi‐Genzyme and UCB; support for meeting attendance or travel from AbbVie, Alexion, Almirall, Eli Lilly, Galderma, Janssen, LEO Pharma, Pfizer, Sanofi‐Genzyme and UCB; and has served on data safety monitoring or advisory boards for AbbVie and Sanofi‐Genzyme. A.T. has served as an advisor, speaker, or investigator for AbbVie, Eli Lilly, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi, and Viatris.

Figures

FIGURE 1
FIGURE 1
Changes in mean SCORAD xerosis score (a), mean xerosis visual analog scale score (b), mean skin hydration index (c), and mean objective SCORAD score (d) during a phase 3 study of a 15% glycerol and 10% liquid paraffin/petrolatum emollient in children with atopic dermatitis [27]. In this study, patients (n = 251) were randomized to apply study emollient or vehicle control twice daily during a 28‐day double‐blind period. Nonresponders on day 28 received study emollient until day 84 (open‐label period); responders on day 28 stopped emollient treatment until day 56 when they were reassessed and resumed study treatment until day 84 if relapse had occurred. Data are shown for responders who worsened and resumed study treatment on day 56. HI, hydration index; SCORAD, SCORing of Atopic Dermatitis index; XS, xerosis score; X‐VAS, xerosis visual analog scale score. Figure reproduced with permission from Boralevi F, et al. J Eur Acad Dermatol Venereol 2014; 28: 1456–62. 2013 John Wiley and Sons. All rights reserved.

Similar articles

Cited by

References

    1. Wollenberg A., Barbarot S., Bieber T., et al., “Consensus‐Based European Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis) in Adults and Children: Part I,” Journal of the European Academy of Dermatology and Venereology 32 (2018): 657–682. - PubMed
    1. Chylla R., Schnopp C., and Volz T., “Basic Skin Care in Atopic Dermatitis – New and Established Treatment Options,” Journal der Deutschen Dermatologischen Gesellschaft 16 (2018): 976–979. - PubMed
    1. Wollenberg A., Kinberger M., Arents B., et al., “European Guideline (EuroGuiDerm) on Atopic Eczema: Part I – Systemic Therapy,” Journal of the European Academy of Dermatology and Venereology 36 (2022): 1409–1431. - PubMed
    1. Wollenberg A., Kinberger M., Arents B., et al., “European Guideline (EuroGuiDerm) on Atopic Eczema – Part II: Non‐Systemic Treatments and Treatment Recommendations for Special AE Patient Populations,” Journal of the European Academy of Dermatology and Venereology 36 (2022): 1904–1926. - PubMed
    1. Augustin M., Wilsmann‐Theis D., Körber A., et al., “Diagnosis and Treatment of Xerosis Cutis—A Position Paper,” Journal der Deutschen Dermatologischen Gesellschaft 17 (2019): 3–33. - PubMed

MeSH terms

LinkOut - more resources